SYDNEY, March 10, 2014 /PRNewswire/ -- Novogen
Limited (ASX: 'NRT'; NASDAQ: 'NVGN'), an oncology drug development
company, announced today it has been selected to present at the
Cavendish Global Health Impact Forum taking place May 5-7 at the United Nations Headquarters in New
York. The purpose of the Forum is to help family offices and
foundations develop and implement their individual pro-social
impact investing, grant-giving, and philanthropy programs within
health and the life sciences.
To accomplish this mission the Forum showcases presentations and
panel discussions by leading scientists, accomplished healthcare
delivery professionals, health-policy experts and private-sector
companies engaged in developing innovations with the potential for
transformational impact on disease prevention, diagnosis and
treatment.
"With the help of our expert advisors, we conduct a global
search of research institutions and private-sector companies in
order to identify organizations that meet the required standard of
excellence," said Michael Moffat,
Cavendish co-founder and President. "The quality and
originality of Novogen's research and scientific insights in cancer
positions them to make a major contribution to the treatment of
adult and pediatric cancers."
"We are honored to be selected to present at this unique event,
and it is further recognition of our innovative approach to
treating – and possibly curing – many of the most pervasive and
deadly forms of cancer afflicting populations around the world
today," said Graham Kelly, PhD,
Novogen CEO and Executive Chairman. "We welcome the chance to
interact with many of world's leading scientific minds,
thought-leaders and generous philanthropic individuals and families
who are all dedicated to the common cause of improving the health
and lives of people around the world."
"Cavendish Global consists of over 150 leading family
offices and foundations from around the world with combined assets
of over $190 billion who share a
passion for pro-social endeavors within health and the
life sciences," Mr. Moffat explained.
The Cavendish Global Health Impact Forum provides family
offices with a discrete, peer-to-peer knowledge expansion and
relationship building environment, combined with the information
and educational resources required by foundations actively
seeking to accelerate technological innovation and health access
through sustainable philanthropy, grant-making and impact
investing. The Forum is also an opportunity for family
offices to champion and share information on projects and
organizations, which they are passionate about with other family
offices from around the world. Cavendish Global together with
the Global Partnerships Forum and the New York Academy of
Sciences organizes the Forum annually in New York.
About Novogen
Novogen is a public, Australian biotechnology company whose
shares trade on both the Australian Securities Exchange ('NRT') and
NASDAQ ('NVGN'). The Company is based in Sydney, Australia, and with a U.S. office in
New Haven, Connecticut. The
Company has two main drug technology platforms known as
super-benzopyrans (SBP) and anti-tropomyosins (ATM). SBP drugs
target cancer stem cells and are being developed for the treatment
of ovarian cancer and glioblastoma. ATM drugs target the cancer
cell cytoskeleton and are being developed for the treatment of
melanoma, prostate cancer, ovarian cancer and neuroblastoma.
Novogen has entered into a joint venture with Yale University known as CanTx Inc. with the aim of
developing personalized chemotherapy for patients with ovarian
cancer.
Further information is available on the Company's website,
www.novogen.com.
About Cavendish Global
Cavendish Global provides family offices and their
foundations with a discrete, peer-to-peer knowledge expansion and
relationship building environment, combined with the innovative
resources required to help develop and implement their
individual pro-social impact investment, grant making and
philanthropy programs within health and the life sciences.
Cavendish Global provides family offices with a number of
innovative resources, which includes Cavendish Impact Forums.
A unique gathering of leading family offices, Cavendish
Impact Forums take place three times each year; in the United
States (NYC, May 2014),
Europe (London, October
2014) and a third event held at a Cavendish Host Partner City
which moves to a different global location each
year (Dubai, UAE January 2015).
For more information: http://cavendishglobal.com
For Further
Information Contact:
|
|
|
Investors
|
Media
|
In the
USA
David Carey/Tanner
Kaufman
Lazar
Partners
+1
212-867-1762
Novogen@lazarpartners.com
In
Australia
Rudi
Michelson
Monsoon
Communications
03 9620
3333
rudim@monsoon.com.au
|
In the
USA
Hollister
Hovey/Allison Parks
Lazar
Partners
+ 1
212-867-1762
Novogen@lazarpartners.com
In
Australia
Dr Douglas
Pretsell
Instinctif
Partners
+61 (0)3 9657
0706
In
ROW
Sue Charles/Stefanie
Bacher
Instinctif
Partners
+44 (0)20 7457
202
|
Logo -
http://photos.prnewswire.com/prnh/20131220/NY36990LOGO
SOURCE Novogen Limited